Dong Yang Guang Pharmaceutical's Ganjing Insulin Injection was approved for listing by the US FDA.

On May 4th, Dongyang Pharmaceutical announced that its independently developed and produced Ganjing Insulin Injection has officially received approval from the US Food and Drug Administration for listing, becoming the fourth Ganjing insulin product to be listed in the US and the first Chinese insulin product to enter the US market. The product has also been granted a "substitutable" label, allowing it to be directly substituted for the original drug Lantus at the pharmacy level.